

5th October 2017

Announcements
National Stock Exchange of Australia
PO Box 283
Newcastle NSW 2300

IQNOVATE LTD – New license agreement signed for the MENA region

iQnovate Ltd (NSX: IQN) announces that, through its fully owned subsidiary Bio Diagnostics MENA Pty Ltd, it has signed a preliminary agreement for the development, commercialization and distribution of its diagnostic platform technology in the Middle East and North Africa region (MENA). The first test to be commercialized in the MENA region is a Salivary Glucose Biosensor and it is proposed that it will be marketed across 19 countries in the MENA region.

The counterparty to this agreement is a newly founded corporation, Seed Mena General trading LLC which is owned by Mr Hisham Algurg, who is managing the private investments and strategic partnership activities of Sheikh Saeed Al Maktoum. He is also the Executive Counselor of Al Fajer Investments & Development, an investment division of Al Fajer Enterprises, a holding group of companies owned by His Highness Sheikh Hasher Al Maktoum. Both Sheikhs are members of the royal family of Dubai. Mr Algurg is also the UAE sponsor of the Chinese petroleum giant “Sinopec Petroleum”. Sinopec is one of the five largest energy corporations in the world, headquartered in Beijing.

Investor Relations

For further information, please contact:

Investor Relations Team
Email: investor.relations@theiqgroup.com.au
Phone: +61 2 8239 5400

Safe Harbor Statement

Any statement in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the deferral securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with iQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia

SOURCE - iQnovate Ltd

iQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.



Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.